Wednesday, July 8, 2026

pharma · No medical condition. · Breast cancer

George Institute for

George Institute for clinical programs — 406 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Sydney, NSW 2042, AU HQ
1999 Founded
841 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Sydney, NSW 2042, AU
Founded
1999
Employees
841
Programs
406
Drugs
522
Patents
0
Intelligence · Clinical Programs

George Institute for projects

406 ClinicalTrials.gov programs sponsored by George Institute for.

George Institute for has 406 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

Page 9 of 9
  1. RC-P0055

    The George Institute

    Adults patients suffering from rheumatoid arthritis and in adequate response to one or two targeted treatments.

    approved small molecule active

    1 trial
  2. RC-P0103

    The George Institute

    lumbosacral radiculalgia

    approved small molecule active

    1 trial
  3. RIBOCICLIB, Kisqali 200 mg film-coated tablets

    The George Institute

    Hormone receptor–positive (HRpos)/human epidermal growth factor receptor 2–negative (HER2neg) early breast cancer at risk of recurrence

    approved small molecule active

    1 trial
  4. ROPIDOL

    The George Institute

    lumbar arthrodesis

    approved small molecule active

    1 trial
  5. ROSUVASTATIN for CHRONIC INFLAMMATORY RHEUMATIC…

    The George Institute

    CHRONIC INFLAMMATORY RHEUMATIC DISEASE: rheumatoid arthritis or psoriatic arthritis or axial spondyloarthritis or systemic lupus erythematosus

    approved small molecule active

    1 trial
  6. Rabipur Pulver und Lösungsmittel zur Herstell...

    The George Institute

    rabies pre-exposure prophylaxis

    approved small molecule active

    1 trial
  7. Renoir

    The George Institute

    Covid-19 infection

    approved small molecule active

    1 trial
  8. SAFE-BK

    The George Institute

    BK Polyomavirus DNAemia after kidney transplantation

    approved small molecule active

    1 trial
  9. SEDA

    The George Institute

    Patients with major depressive episode and moderate to severe insomnia disorder

    approved small molecule active

    1 trial
  10. SILDENAFIL , LEVOTHYROXINE SODIUM

    The George Institute

    erectile function, hypothyroidism subclinic

    approved small molecule active

    1 trial
  11. SIMA SPK 01

    The George Institute

    End-stage kidney disease in Type 1 diabetes, SIROLIMUS VERSUS MYCOPHENOLATE MOFETIL IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE RISK OF HERNIA

    approved small molecule active

    1 trial
  12. SINECATECHINS

    The George Institute

    Anal high-grade squamous intraepithelial lesions (HSIL).

    approved small molecule active

    1 trial
  13. TESTOGEL for low ovarian reserve according t…

    The George Institute

    low ovarian reserve according to Bologna criteria and carriers of androgen receptor polymorphism

    approved small molecule active

    1 trial
  14. TRANEXAMIC ACID

    The George Institute

    Hip fracture

    approved small molecule active

    1 trial
  15. TRAPEZIUS

    The George Institute

    TRAPEZIUS MYOFASCIAL SYNDROME IN FIBROMYALGIA PATIENTS

    approved small molecule active

    1 trial
  16. TailorDose-II

    The George Institute

    Breast cancer female NOS

    approved small molecule active

    1 trial
  17. Trangorex 200 mg comprimidos

    The George Institute

    Atrial fibrillation

    approved small molecule active

    1 trial
  18. Ultomiris 300 mg/30 mL concentrate for solution for infusion

    The George Institute

    IgA nephropathy

    approved small molecule active

    1 trial
  19. Vabysmo 120 mg/mL solution for injection in pre-filled syringe

    The George Institute

    SUBRETINAL HYPERREFLECTIVE MATERIAL

    approved small molecule active

    1 trial
  20. Vyvgart 20 mg/mL concentrate for solution for infusion

    The George Institute

    Patients affected by generalized myasthenia gravis

    approved small molecule active

    1 trial
  21. Wegovy 2.4 mg solution for injection in pre-filled pen

    The George Institute

    obstructive sleep apnea

    approved small molecule active

    1 trial
  22. Xtandi - 40 mg soft capsules

    The George Institute

    PROSTATE CANCER

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does George Institute for have?

406 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.